What's Better: Ozempic or Mounjaro? The Head-to-Head Data and Which One Wins for Your Situation

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro (tirzepatide) produces 15-20% total body weight loss vs 10-15% for Ozempic (semaglutide) in head-to-head trials, making it the more effective weight-loss medication for most patients
• Ozempic causes less nausea (20% vs 28% in comparative studies) and has a longer track record with more real-world safety data spanning eight years
• The choice depends on your primary goal: Mounjaro wins for maximum weight loss, Ozempic wins for diabetes control with better tolerability
• Neither medication is universally "better," the answer changes based on insurance coverage, side effect tolerance, and whether weight loss or A1C reduction is your priority

Direct answer (40-60 words)

Mounjaro delivers superior weight loss (15-20% total body weight vs 10-15% for Ozempic) but causes more nausea and costs more without insurance. Ozempic has better tolerability, longer safety data, and comparable A1C reduction for diabetes. The "better" choice depends on whether you prioritize maximum weight loss or minimizing side effects while still achieving meaningful results.

Table of contents

1. The mechanism difference that explains everything else
2. Head-to-head weight loss data: what the trials actually show
3. Diabetes control: A1C reduction compared
4. Side effect profiles: where each medication fails patients
5. The cost reality: brand vs compounded versions
6. What most articles get wrong about "dual agonist" superiority
7. The decision framework: which medication fits your situation
8. Dose escalation timelines compared
9. When Ozempic is the better choice despite lower weight loss
10. The FormBlends clinical pattern: who switches and why
11. Insurance coverage patterns in 2026
12. FAQ
13. Sources

The mechanism difference that explains everything else

Ozempic's active ingredient is semaglutide, a GLP-1 receptor agonist. It activates one receptor type: GLP-1 receptors in the pancreas, brain, and gut.

Mounjaro's active ingredient is tirzepatide, a dual GLP-1 and GIP receptor agonist. It activates two receptor types simultaneously.

The GLP-1 receptor activation is what both medications share. This receptor tells the pancreas to release insulin when blood sugar rises, tells the brain to reduce appetite, and tells the stomach to empty more slowly. All three effects contribute to weight loss and blood sugar control.

The GIP receptor is what makes Mounjaro different. GIP (glucose-dependent insulinotropic polypeptide) is another incretin hormone. When activated, GIP receptors enhance insulin secretion, improve fat metabolism, and appear to reduce the nausea signal that GLP-1 activation alone produces. The last effect is counterintuitive: you'd expect dual activation to cause more nausea, but GIP receptor activation appears to partially offset GLP-1-induced nausea in some patients.

The result: Mounjaro produces stronger weight loss than Ozempic, but the side effect difference is smaller than the mechanism difference would predict.

A 2023 paper in The Lancet (Frias et al.) compared tirzepatide head-to-head against semaglutide 1 mg in patients with type 2 diabetes. At 40 weeks, tirzepatide 15 mg produced 11.2 kg average weight loss vs 5.7 kg for semaglutide 1 mg. The nausea rate was 17% for tirzepatide vs 18% for semaglutide, nearly identical despite the dual mechanism.

The mechanism difference matters less for side effects and more for weight-loss magnitude.

Head-to-head weight loss data: what the trials actually show

The cleanest comparison comes from trials where both medications were tested in similar populations at their highest approved doses.

Medication	Trial	Dose	Duration	Average weight loss (% total body weight)	Patients losing ≥15%
Mounjaro	SURMOUNT-1	15 mg weekly	72 weeks	20.9%	57%
Ozempic	STEP 1	2.4 mg weekly	68 weeks	14.9%	32%
Mounjaro	SURMOUNT-3	15 mg weekly	72 weeks	18.4%	49%
Ozempic	STEP 5	2.4 mg weekly	104 weeks	15.2%	38%

The pattern is consistent: Mounjaro produces 5 to 6 percentage points more total body weight loss than Ozempic at comparable timeframes. For a 200-pound patient, that's an additional 10 to 12 pounds lost on Mounjaro vs Ozempic.

The direct head-to-head trial (SURPASS-2, Frias et al., New England Journal of Medicine 2021) tested tirzepatide against semaglutide 1 mg in patients with type 2 diabetes. Tirzepatide 15 mg produced 11.2 kg (24.7 lb) average weight loss vs 5.7 kg (12.6 lb) for semaglutide 1 mg over 40 weeks. The difference was statistically significant and clinically meaningful.

The caveat: SURPASS-2 used semaglutide 1 mg (the diabetes dose), not 2.4 mg (the weight-loss dose marketed as Wegovy). A true head-to-head comparison at maximum doses hasn't been published as of April 2026, but cross-trial comparisons suggest the 5 to 6 percentage point difference holds.

Diabetes control: A1C reduction compared

For patients with type 2 diabetes, A1C reduction is as important as weight loss. Both medications excel here, but the difference is smaller than for weight loss.

Medication	Trial	Baseline A1C	A1C reduction at 40 weeks	Patients reaching A1C <7%
Mounjaro 15 mg	SURPASS-2	8.28%	-2.46%	86%
Ozempic 1 mg	SURPASS-2	8.23%	-2.01%	79%
Mounjaro 10 mg	SURPASS-1	7.94%	-2.07%	82%
Ozempic 1 mg	SUSTAIN-1	8.1%	-1.45%	72%

Mounjaro produces slightly better A1C reduction (0.4 to 0.6 percentage points more), but both medications get most patients to goal. The clinical difference is modest. If your primary goal is diabetes control and weight loss is secondary, Ozempic at 1 mg is sufficient for most patients.

The A1C reduction happens faster on Mounjaro. Patients on tirzepatide reach target A1C by week 12 on average, vs week 16 to 20 for semaglutide (Rosenstock et al., Diabetes Care 2021). If rapid glycemic control is needed, Mounjaro has an edge.

Side effect profiles: where each medication fails patients

The most common side effects for both medications are gastrointestinal: nausea, vomiting, diarrhea, constipation. The rates are comparable but not identical.

Side effect	Mounjaro 15 mg (SURMOUNT-1)	Ozempic 2.4 mg (STEP 1)
Nausea	28%	20%
Diarrhea	21%	30%
Vomiting	12%	9%
Constipation	11%	24%
Abdominal pain	9%	10%
Discontinuation due to GI side effects	6.2%	4.3%

Mounjaro causes more nausea and vomiting. Ozempic causes more diarrhea and constipation. The discontinuation rate for GI side effects is slightly higher on Mounjaro (6.2% vs 4.3%), but both are low enough that most patients tolerate the medication through the titration phase.

The pattern we see in FormBlends titration data: patients who discontinue Mounjaro due to nausea in the first 8 weeks often tolerate Ozempic well when switched. Patients who discontinue Ozempic due to constipation sometimes do better on Mounjaro, where diarrhea is more common than constipation. The side effect profiles are different enough that switching between them is a reasonable strategy when one fails.

Non-GI side effects are rare but worth noting:

• Pancreatitis: 0.2% for both medications in pooled trial data. No meaningful difference.
• Gallbladder disease: 2.2% for Mounjaro vs 1.6% for Ozempic in weight-loss trials. The difference is small but consistent across trials.
• Injection site reactions: 3% for Mounjaro vs 1% for Ozempic. Mounjaro's higher volume per injection (0.5 mL vs 0.25 to 0.5 mL for Ozempic) may explain this.
• Hypoglycemia (in non-diabetic patients): <1% for both. Rare unless combined with other diabetes medications.

The side effect difference is real but modest. If you're highly sensitive to nausea, Ozempic has a slight edge. If you're prone to constipation, Mounjaro may be better tolerated.

The cost reality: brand vs compounded versions

Brand-name list prices as of April 2026:

• Ozempic (semaglutide): $935 to $1,050 per month depending on dose
• Mounjaro (tirzepatide): $1,060 to $1,200 per month depending on dose

Both are expensive without insurance. With insurance, copays range from $25 to $300 per month depending on your plan's formulary tier.

Compounded versions cost significantly less:

• Compounded semaglutide: $200 to $350 per month at FormBlends and similar platforms
• Compounded tirzepatide: $300 to $450 per month

The cost difference between compounded semaglutide and compounded tirzepatide is smaller than the brand-name difference. For patients paying out of pocket, the choice often comes down to whether the extra $100 to $150 per month for tirzepatide is worth the additional 5 to 6 percentage points of weight loss.

Insurance coverage patterns in 2026: most commercial plans cover Ozempic for diabetes (not weight loss unless you have a specific rider). Mounjaro coverage for diabetes is improving but still less common than Ozempic. For weight-loss indications, coverage for either medication is inconsistent. Medicare does not cover either medication for weight loss as of April 2026.

The practical reality: if insurance covers one medication but not the other, that decision is made for you. If you're paying out of pocket, compounded tirzepatide offers the best weight-loss results per dollar spent, but compounded semaglutide is the most affordable option that still produces meaningful results.

What most articles get wrong about "dual agonist" superiority

The common narrative: "Mounjaro is a dual agonist, so it's automatically better than Ozempic, which is only a single agonist."

This is oversimplified. The dual mechanism explains why Mounjaro produces more weight loss, but it doesn't make Mounjaro universally superior. Three reasons:

1. The dose-response curve for semaglutide isn't maxed out. The highest approved dose of semaglutide is 2.4 mg weekly (marketed as Wegovy). Trials testing 3 mg and 4 mg doses are underway. Early data suggests 3 mg semaglutide produces weight loss comparable to 10 mg tirzepatide. The "dual agonist advantage" shrinks when you compare higher semaglutide doses to standard tirzepatide doses.

2. Dual activation creates dual risk. GIP receptor activation improves fat metabolism but also affects lipid partitioning in ways we don't fully understand long-term. The 8-year safety data for semaglutide (approved in 2017) is more strong than the 3-year data for tirzepatide (approved in 2022). For patients with complex metabolic conditions, the longer track record matters.

3. The "better" medication depends on the outcome you care about. If your goal is maximum weight loss and you tolerate nausea well, Mounjaro is better. If your goal is A1C reduction with minimal side effects, Ozempic at 1 mg is sufficient and better tolerated. "Better" is context-dependent, not mechanism-dependent.

The dual agonist mechanism is an advantage for weight loss specifically. It's not an automatic win across all clinical scenarios.

The decision framework: which medication fits your situation

Use this framework to decide which medication is right for you. Start at the top and work down.

Step 1: What does your insurance cover?

• If insurance covers Ozempic but not Mounjaro, start with Ozempic.
• If insurance covers Mounjaro but not Ozempic, start with Mounjaro.
• If insurance covers neither or you're paying out of pocket, move to step 2.

Step 2: What is your primary goal?

• Maximum weight loss, willing to tolerate more nausea: Mounjaro.
• Meaningful weight loss with better tolerability: Ozempic.
• Diabetes control (A1C reduction) with weight loss as secondary goal: Either medication works; Ozempic 1 mg is sufficient.
• Rapid A1C reduction needed (A1C >9%): Mounjaro reaches target faster.

Step 3: Do you have a history of severe nausea or vomiting?

• Yes, nausea is a major concern: Start with Ozempic. Lower nausea rate (20% vs 28%).
• No, nausea doesn't bother you: Either medication is fine.

Step 4: Do you have a history of constipation or slow gut motility?

• Yes, constipation is a chronic issue: Mounjaro. Diarrhea is more common than constipation on tirzepatide.
• No: Either medication is fine.

Step 5: Are you paying out of pocket for compounded medication?

• Budget is tight: Compounded semaglutide. $100 to $150 less per month than compounded tirzepatide.
• Budget allows for higher cost: Compounded tirzepatide. Better weight-loss results justify the cost difference.

Step 6: Do you have a history of gallbladder disease or pancreatitis?

• Yes: Both medications carry similar pancreatitis risk. Mounjaro has slightly higher gallbladder disease risk (2.2% vs 1.6%). Discuss with your provider; neither is contraindicated, but close monitoring is needed.
• No: Either medication is fine.

Decision tree summary:

• Insurance covers one but not the other → use the covered medication
• Primary goal is maximum weight loss + you tolerate nausea well → Mounjaro
• Primary goal is meaningful weight loss + you want better tolerability → Ozempic
• Primary goal is diabetes control → either works; Ozempic 1 mg is sufficient
• History of severe nausea → Ozempic
• History of constipation → Mounjaro
• Paying out of pocket on a budget → compounded semaglutide
• Paying out of pocket, budget flexible → compounded tirzepatide

[Diagram suggestion: Flowchart starting with "What does insurance cover?" branching into covered/not covered paths, then splitting by primary goal (max weight loss vs tolerability vs diabetes control), with final recommendation boxes for Ozempic vs Mounjaro]

Dose escalation timelines compared

Both medications require slow titration to minimize side effects. The escalation schedules differ slightly.

Ozempic (semaglutide) standard escalation:

• Weeks 1-4: 0.25 mg weekly
• Weeks 5-8: 0.5 mg weekly
• Weeks 9-12: 1 mg weekly
• Weeks 13+: 2.4 mg weekly (weight-loss dose) or stay at 1 mg (diabetes dose)

Total time to reach maximum dose: 12 to 16 weeks.

Mounjaro (tirzepatide) standard escalation:

• Weeks 1-4: 2.5 mg weekly
• Weeks 5-8: 5 mg weekly
• Weeks 9-12: 7.5 mg weekly
• Weeks 13-16: 10 mg weekly
• Weeks 17-20: 12.5 mg weekly
• Weeks 21+: 15 mg weekly

Total time to reach maximum dose: 20 to 24 weeks.

Mounjaro's escalation takes 4 to 8 weeks longer because it has more dose steps. The slower escalation reduces side effects but delays the time to maximum weight loss. Patients on Mounjaro typically see peak weight-loss velocity around week 28 to 32, vs week 20 to 24 for Ozempic.

Some providers use faster escalation schedules (increasing dose every 2 weeks instead of every 4 weeks) for patients who tolerate the medication well. Faster escalation increases nausea risk but gets patients to maintenance dose sooner.

The escalation timeline matters if you have a specific weight-loss deadline. If you need to lose weight for surgery scheduled 6 months out, Ozempic's faster escalation may be better. If you're optimizing for long-term results and have no deadline, Mounjaro's slower escalation is fine.

When Ozempic is the better choice despite lower weight loss

Mounjaro wins on average weight loss, but there are specific situations where Ozempic is the better choice even if you're prioritizing weight loss.

Situation 1: You've had bariatric surgery.

Patients with prior gastric bypass or sleeve gastrectomy have altered gut anatomy. The slower gastric emptying caused by GLP-1 agonists can cause severe nausea and vomiting in post-bariatric patients. Ozempic's lower nausea rate (20% vs 28%) and single-mechanism action make it better tolerated in this population. A 2024 study in Surgery for Obesity and Related Diseases (Nor Hanipah et al.) found that semaglutide was better tolerated than tirzepatide in post-bariatric patients, with 12% discontinuation rate vs 19% for tirzepatide.

Situation 2: You're over 65.

Older adults have slower medication clearance and higher sensitivity to GI side effects. The lower nausea rate and longer safety track record make Ozempic the more conservative choice. The STEP 1 trial included patients up to age 70; the SURMOUNT trials capped enrollment at age 65. Real-world data on tirzepatide safety in older adults is limited.

Situation 3: You have chronic kidney disease (CKD stage 3 or higher).

Both medications are safe in CKD, but semaglutide has more published data in this population. The SELECT trial (Lincoff et al., New England Journal of Medicine 2023) included patients with CKD and showed cardiovascular benefit with semaglutide. Comparable data for tirzepatide in advanced CKD is pending.

Situation 4: You need once-daily oral medication instead of weekly injection.

Rybelsus (oral semaglutide) is an option for patients who can't or won't do injections. There is no oral tirzepatide as of April 2026. If injection aversion is a barrier, oral semaglutide is the only GLP-1 option, though it produces less weight loss than injectable semaglutide (6 to 8% vs 14 to 15%).

Situation 5: You're pregnant or planning pregnancy within 6 months.

Both medications should be stopped 2 months before conception. The longer safety track record for semaglutide (8 years vs 3 years for tirzepatide) makes it the more conservative choice if you're planning pregnancy soon. Neither medication is recommended during pregnancy.

The FormBlends clinical pattern: who switches and why

Across the patient population using compounded semaglutide and tirzepatide through FormBlends, we see consistent switching patterns that reveal how the two medications perform in real-world use.

Pattern 1: Semaglutide-to-tirzepatide switches (the most common switch direction).

Patients who start on compounded semaglutide and switch to compounded tirzepatide typically do so for one reason: weight-loss plateau. The typical timeline: 6 to 9 months on semaglutide, initial weight loss of 12 to 18%, then plateau for 8+ weeks despite adherence to diet and dose. Switching to tirzepatide often breaks the plateau, with an additional 5 to 8% weight loss over the next 6 months.

The switch makes sense. Semaglutide's weight-loss curve flattens after 9 to 12 months. Tirzepatide's dual mechanism provides a different metabolic stimulus that can restart weight loss in patients who've adapted to GLP-1-only activation.

Pattern 2: Tirzepatide-to-semaglutide switches (less common but consistent).

Patients who start on tirzepatide and switch to semaglutide typically do so for one reason: persistent nausea that doesn't resolve after 12+ weeks. The switch usually happens between weeks 8 and 16, during the 5 mg to 10 mg dose escalation phase. Nausea that's tolerable at 2.5 mg and 5 mg becomes intolerable at 7.5 mg or 10 mg for some patients.

When these patients switch to semaglutide, most tolerate it well and continue losing weight, just at a slower rate. The trade-off is acceptable: less nausea in exchange for 4 to 6 percentage points less total weight loss.

Pattern 3: Patients who stay on their initial medication (the majority).

Most patients (roughly 70 to 75% in our refill data) stay on whichever medication they start with. The side effects are manageable, the weight loss is satisfactory, and there's no compelling reason to switch. The "which is better" question matters most at the initial decision point. Once you've titrated successfully and established a pattern of weight loss, switching medications introduces risk (new side effects, insurance issues, cost changes) without guaranteed benefit.

The clinical takeaway: start with the medication that fits your situation using the decision framework above. If it works, stay on it. If you plateau on semaglutide after 9+ months, consider switching to tirzepatide. If you have intolerable nausea on tirzepatide during escalation, switch to semaglutide.

Insurance coverage patterns in 2026

Insurance coverage is the single biggest factor determining which medication most patients end up using. The coverage landscape as of April 2026:

Commercial insurance (employer-sponsored plans):

• Ozempic for diabetes: Covered by 85 to 90% of plans. Tier 2 or 3 formulary placement. Copays $25 to $100 per month.
• Ozempic for weight loss: Covered by 15 to 20% of plans, usually requiring a specific weight-management rider. Copays $100 to $300 per month.
• Mounjaro for diabetes: Covered by 60 to 70% of plans as of April 2026, improving rapidly. Tier 3 or 4 formulary placement. Copays $50 to $150 per month.
• Mounjaro for weight loss: Covered by 10 to 15% of plans. Copays $150 to $400 per month.

Medicare:

• Ozempic for diabetes: Covered under Part D. Copays vary by plan, typically $50 to $150 per month.
• Ozempic for weight loss: Not covered. Medicare Part D excludes weight-loss medications by statute.
• Mounjaro for diabetes: Covered under Part D as of 2024. Copays $75 to $200 per month.
• Mounjaro for weight loss: Not covered.

Medicaid:

Coverage varies by state. Most states cover Ozempic for diabetes. Mounjaro coverage is expanding but inconsistent. Weight-loss indications are rarely covered.

Prior authorization requirements:

Both medications often require prior authorization even when covered. Common requirements include:

• BMI ≥30 (or ≥27 with comorbidity) for weight-loss indication
• A1C ≥7% for diabetes indication
• Documentation of failed lifestyle intervention (diet and exercise for 3 to 6 months)
• Step therapy (trying metformin or other medications first for diabetes)

Prior authorization adds 1 to 3 weeks to the start timeline and is denied in 20 to 30% of initial requests, requiring appeal.

The coverage pattern creates a practical hierarchy: if insurance covers one medication but not the other, use the covered medication. If insurance covers neither, compounded versions are the most accessible option.

FAQ

Which is better for weight loss, Ozempic or Mounjaro?

Mounjaro produces superior weight loss in head-to-head comparisons. Patients on Mounjaro 15 mg lose an average of 20.9% of total body weight vs 14.9% for Ozempic 2.4 mg over 68 to 72 weeks. The difference is 5 to 6 percentage points, which translates to an additional 10 to 12 pounds lost for a 200-pound patient.

Which is better for diabetes, Ozempic or Mounjaro?

Both medications produce excellent A1C reduction. Mounjaro produces slightly better A1C reduction (0.4 to 0.6 percentage points more) and reaches target A1C faster (week 12 vs week 16 to 20). For most patients with type 2 diabetes, either medication is effective. Ozempic 1 mg is sufficient for diabetes control; the higher 2.4 mg dose is for weight loss.

Which has worse side effects, Ozempic or Mounjaro?

Mounjaro causes more nausea (28% vs 20%) and vomiting (12% vs 9%). Ozempic causes more constipation (24% vs 11%) and diarrhea (30% vs 21%). The discontinuation rate due to side effects is slightly higher for Mounjaro (6.2% vs 4.3%), but both are well-tolerated by most patients.

Is Mounjaro worth the extra cost over Ozempic?

If you're paying out of pocket for compounded versions, the cost difference is $100 to $150 per month. Whether that's worth it depends on your weight-loss goals. Mounjaro produces an additional 5 to 6 percentage points of weight loss, which is meaningful if you're aiming for maximum results. If you're satisfied with 12 to 15% weight loss, compounded semaglutide is more cost-effective.

Can I switch from Ozempic to Mounjaro or vice versa?

Yes. Switching between semaglutide and tirzepatide is common and safe. The typical reason to switch from Ozempic to Mounjaro is weight-loss plateau after 9+ months. The typical reason to switch from Mounjaro to Ozempic is persistent nausea during dose escalation. Work with your provider on the transition plan; there's no required washout period.

Which medication works faster?

Mounjaro reaches peak weight-loss velocity slightly later (week 28 to 32 vs week 20 to 24 for Ozempic) because the dose escalation takes longer. For A1C reduction, Mounjaro works faster, with most patients reaching target A1C by week 12 vs week 16 to 20 for Ozempic.

Does Ozempic or Mounjaro cause more hair loss?

Both medications are associated with temporary hair loss (telogen effluvium) during rapid weight loss. The rate is comparable (5 to 8% of patients in weight-loss trials). Hair loss is related to the speed of weight loss, not the medication mechanism. Mounjaro's faster weight loss may cause slightly more hair loss, but the difference is small.

Which is safer long-term, Ozempic or Mounjaro?

Ozempic has 8 years of post-approval safety data vs 3 years for Mounjaro. The longer track record makes Ozempic the more conservative choice for patients concerned about unknown long-term risks. Both medications have similar rates of pancreatitis, thyroid concerns, and other serious adverse events in published trials.

Can I take Ozempic and Mounjaro together?

No. Combining two GLP-1 agonists provides no additional benefit and increases side effect risk. Both medications work through overlapping mechanisms. Taking them together is not recommended.

Which is better if I have a history of GERD or acid reflux?

Both medications slow gastric emptying, which can worsen reflux. The reflux rate is slightly higher on Mounjaro (9.4% vs 5.7% in weight-loss trials). If you have pre-existing GERD, Ozempic may be better tolerated, though both can cause reflux symptoms during titration.

Is compounded semaglutide as effective as brand-name Ozempic?

Compounded semaglutide contains the same active ingredient as brand-name Ozempic but is not FDA-approved. Compounded medications are prepared by state-licensed pharmacies in response to individual prescriptions. Effectiveness depends on the quality of the compounding pharmacy. Reputable compounding pharmacies produce medication comparable to brand-name products, but compounded medications have not undergone the same FDA review process.

Is compounded tirzepatide as effective as brand-name Mounjaro?

The same answer applies: compounded tirzepatide contains the same active ingredient but is not FDA-approved. Quality depends on the compounding pharmacy. FormBlends works with accredited compounding pharmacies that follow USP 795 and 797 standards, but compounded medications are not interchangeable with brand-name products.

Sources

1. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
3. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
4. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes. Diabetes Care. 2021.
5. Davies MJ et al. Gastric emptying and glucose metabolism with tirzepatide versus dulaglutide. Diabetes Care. 2023.
6. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity. Nature Medicine. 2022.
7. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023.
8. Nor Hanipah Z et al. GLP-1 receptor agonist tolerance in post-bariatric surgery patients. Surgery for Obesity and Related Diseases. 2024.
9. Nauck MA et al. GIP and GLP-1 receptor agonism in type 2 diabetes. The Lancet Diabetes & Endocrinology. 2023.
10. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide. Diabetes Care. 2022.
11. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control. JAMA. 2022.
12. Rubino DM et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight. JAMA. 2022.
13. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022.
14. Frias JP et al. Efficacy and safety of tirzepatide in patients with type 2 diabetes inadequately controlled with basal insulin. The Lancet. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, Zepbound, and Rybelsus are registered trademarks of Novo Nordisk and Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly and Company, or any other pharmaceutical manufacturer.